FDA approves Pfizer’s Vyndaqel, Vyndamax for cardiomyopathy in rare protein disorder
An analyst wrote that the drug's high price tag of $225,000 could limit its uptake in ATTR-CM, but it could become competitive with Alnylam's Onpattro.
Alnylam, Regeneron form $1B partnership to develop eye, central nervous system drugs
The deal will focus on discovery, development and commercialization of CNS and eye drugs and also includes development of two C5-targeting drugs in liver disease. The companies have an existing partnership centered on NASH drugs.
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
FDA approves Alnylam’s siRNA drug Onpattro for rare disorder
The drug is the first approved treatment for the condition, as well as the first siRNA drug to win the agency's approval.
Alnylam stages a comeback with positive late-stage study results for RNAi treatment Patisiran
Promising Phase 3 study results for its RNAi treatment, called Patisiran, for a rare, genetic nerve disorder have increased the chances that Alnylam could be the first to commercialize a RNAi drug.
Health insurers fought reform with $86.2M (Morning Read)
Health insurers last year gave the U.S. Chamber of Commerce $86.2 million that was used to oppose the healthcare overhaul law, according to tax records and people familiar with the donation, Bloomberg Businessweek reports.
Medtronic’s research partnership: a roadmap to the future?
Last week, CHDI Foundation, a not-for-profit research organization, said it would "initially" pay up to 50 percent of clinical costs of a drug/device therapy being developed by Medtronic and Alnylam Pharmaceutical to treat Huntington's disease. While medical device and biopharmaceutical companies are partnering more and more, the inclusion of the foundation in this trio is what's interesting.
presented by
3D Medical Animation Services: A Revolution in Healthcare Education and Marketing
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.
Medtronic joins with drug company to treat Huntington’s disease
Medtronic Inc. (NYSE:MDT) said Wednesday it will form an alliance with a pharmaceutical firm and research foundation to develop a unique drug/device therapy to treat Huntington's disease. The medical firm, based in Fridley, Minnesota, said it will partner with Alnylam Pharmaceutical Inc. (Nasdaq:ALNY) and the CHDI Foundation to deliver a cutting-edge drug technology directly to the brain using an implantable infusion system being developed by Medtronic.